- 作者：Hirotaka Takasaki ; Chizuko Hashimoto ; Atsuko Fujita ; Kenji Matsumoto ; Jun Taguchi ; Hideyuki Kuwabara ; Etsuko Yamazaki ; Hideyuki Koharazawa ; Hiroyuki Fujita ; Shin Fujisawa ; Yoshimi Ishii ; Wataru Yamamoto ; Shigeki Motomura ; Naoto Tomita ; Yoshiaki Ishigatsubo ; Rika Sakai
- 关键词：Autologous stem cell transplantation ; Diffuse large B-cell lymphoma ; MEAM
- 刊名：Clinical Lymphoma Myeloma and Leukemia
- 出版年：2013
- 出版时间：August, 2013
- 年：2013
- 卷：13
- 期：4
- 页码：404-409
- 全文大小：215 K
Background
Although rituximab added to CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) is the standard chemotherapy for untreated DLBCL, its therapeutic effect is limited in younger patients with high-intermediate risk or high-risk disease according to the age-adjusted international prognostic index. In fact, the efficacy and safety of HDT plus rituximab followed by ASCT for such patients remain unclear.Patients and Methods
We retrospectively investigated the safety and effectiveness of HDT/ASCT in patients with untreated DLBCL. Twenty-two patients, aged 60 years and younger, with untreated DLBCL (classified as high-intermediate [n?=?14 (64 % )] or high [n?=?8 (32 % )] risk) underwent upfront HDT/ASCT between January 2004 and December 2008, achieving either a complete response (CR; n?= 15 (68 % )) or a partial response (PR; n?= 7 (32 % )).
Results
The 5-year overall survival rate was 81.0 % and the progression-free survival rate was 73.0 % , with no significant difference between risk groups based on the international prognostic index. The most common nonhematologic toxicity was febrile neutropenia [n?=?9 (41 % )]. The cause of all 3 fatalities was exacerbation of the underlying disease, and no treatment-related mortality was observed. No variables with a significant influence on overall survival were identified, but a correlation of the treatment response before transplanation with progression-free survival was suggested (CR vs. PR: 92 % vs. 30 % , P?= .002).
Conclusion
These results suggest that adding rituximab to upfront HDT/ASCT is feasible and can improve the outcome in untreated patients with poor-prognosis DLBCL. In the future, upfront HDT/ASCT should be more extensively evaluated in clinical trials.